免疫疗法与分子靶向治疗甲状腺未分化癌的研究进展
Research Progress of Immunotherapy and Molecular Targeted Therapy for Anaplastic Thyroid Carcinoma
刘翔 1杨相立1
作者信息
摘要
甲状腺未分化癌(ATC)属于甲状腺癌的一种病理类型,具有恶性程度高、治疗效果差等特点,目前为止缺乏特效治疗手段.免疫疗法可通过有效激活机体免疫系统来消灭肿瘤,实现持久应答及延长生存期,而分子靶向治疗可针对特异性靶点对肿瘤细胞进行选择性杀伤,且副作用较轻,二者现已成为临床治疗ATC的新思路,获得了高度重视.本文针对免疫疗法及分子靶向治疗ATC的研究进展展开综述,旨在为该病的临床治疗提供参考.
Abstract
Anaplastic Thyroid Carcinoma(ATC)is a pathological type of thyroid cancer,which has the characteristics of high malignancy and poor therapeutic effect.So far,there is no specific treatment.Immunotherapy can effectively activate the body's immune system to eliminate tumors,achieve lasting response and prolong survival time,while molecular targeted therapy can selectively kill tumor cells against specific targets with less side effects.Both of them have become new ideas for clinical treatment of ATC and have received great attention.This paper reviews the research progress of immunotherapy and molecular targeted therapy for ATC,aiming to provide reference for the clinical treatment of this disease.
关键词
甲状腺未分化癌/免疫疗法/分子靶向治疗Key words
Anaplastic thyroid carcinoma/Immunotherapy/Molecular targeted therapy引用本文复制引用
出版年
2024
NETL
NSTL
万方数据